MARKET

DARE

DARE

Dare Bioscience
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.000
+0.011
+1.15%
Pre Market: 1.000 0 0.00% 08:34 07/02 EDT
OPEN
0.9800
PREV CLOSE
0.9886
HIGH
1.020
LOW
0.9800
VOLUME
114.97K
TURNOVER
--
52 WEEK HIGH
2.220
52 WEEK LOW
0.6902
MARKET CAP
26.65M
P/E (TTM)
-1.1227
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DARE stock price target is 4.504 with a high estimate of 7.52 and a low estimate of 3.000.

EPS

DARE News

More
DELL, PLUG among premarket gainers
Seeking Alpha - Article · 06/24 12:14
Daré Bioscience launches late-stage study of lead candidate in bacterial inflammation
Seeking Alpha - Article · 06/17 13:11
AMRN, STWD among premarket gainers
Seeking Alpha - Article · 06/17 12:23
Daré Bioscience Announces Initiation Of Pivotal Phase 3 Study Of DARE-BV1 In Patients With Bacterial Vaginosis
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the initiation of the DARE-BVFREE study, a multi-center,
Benzinga · 06/17 12:02
Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis
Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the initiation of the DARE-BVFREE study, a multi-center, double-blind, placebo-controlled Phase 3 clinical study of DARE-BV1 for the treatment of bacterial vaginosis. DARE-BV
GlobeNewswire · 06/17 12:00
Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive
GlobeNewswire · 06/15 13:00
Dare Bioscience Reports Receipt Of $1.5M Under Current Grant Supplement Award For Continued Development Of User-Controlled Long Acting Reversible Contraceptive
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the receipt by its wholly owned subsidiary of $1.5 million in additional grant funding from the Bill & Melinda
Benzinga · 06/15 12:14
Dare Bioscience (DARE) Investor Presentation - Slideshow
Seeking Alpha - Article · 06/09 21:58

Industry

Biotechnology & Medical Research
-0.32%
Pharmaceuticals & Medical Research
+0.20%

Hot Stocks

Symbol
Price
%Change

About DARE

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.
More

Webull offers kinds of Dare Bioscience Inc stock information, including NASDAQ:DARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DARE stock methods without spending real money on the virtual paper trading platform.